Cash and cash equivalents was approximately $220 million as of December 31, 2021.Full year 2021 revenue was approximately $70 million, primarily from ten revenue units, compared to 2020 revenue of approximately $57 million, primarily from nine revenue units including two system upgrades.Total revenue for the fourth quarter 2021 was approximately $20 million, primarily from three revenue units, compared to approximately $18 million, primarily from three revenue units including one system upgrade, in the fourth quarter of 2020.Total backlog increased to approximately $313 million as of December 31, 2021, compared to approximately $241 million as of December 31, 2020.A total of 28 orders were received for the twelve months ended December 31, 2021, representing a 65% growth over 17 total orders for the twelve months ended December 31, 2020. Received seven new orders for MRIdian systems totaling approximately $41 million, compared to five new orders, including one upgrade, totaling approximately $24 million in the fourth quarter of 2020.Selected Fourth Quarter and Full Year 2021 Preliminary Results and Other Data (Unaudited) The preliminary results have not been audited and are subject to change. (Nasdaq: VRAY) today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2021. Claim your 1-week free trial to StreetInsider Premium here. and ViewRay GmbH are its subsidiaries.Get instant alerts when news breaks on your stocks. MRIdian employs MRI-based technology to provide real-time imaging of tumor from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian also records the level of radiation dose that the treatment area has received. MRIdian combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients. MRIdian system is comprised of three components: the MRI system, the radiation delivery system and an integrated treatment planning and delivery software.
It provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. The MRIdian is a system that integrates radiation therapy with simultaneous magnetic resonance imaging (MRI). designs, manufactures and markets the ViewRay MRIdian.
0 kommentar(er)
